Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone plus empagliflozin vs either agent alone in chronic kidney disease and type 2 diabetes
2021-003037-11Phase 2Active
- Sponsor
- Bayer
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) comparing Finerenone + empagliflozin, Finerenone alone and Empagliflozin alone (3 arms). Primary endpoint: Primary: mean ratio of change in UACR at Day 180 (combination vs empagliflozin alone). Started Feb 2022; status: active.
02
Drugs
finerenoneempagliflozin
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2021-003037-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003037-11.